AbCellera Biologics Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
AbCellera Biologics Inc. (ABCL) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $3.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $1.79M, a 12.84% increase year-over-year.
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $1.82M, a 42.62% increase year-over-year.
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.80M, a 34.51% increase year-over-year.
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.99M, a 44.62% increase year-over-year.
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $6.65M, a 8.15% increase from fiscal 2024.
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $6.15M, a 5.39% decline from fiscal 2023.
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $6.50M, a 23.58% increase from fiscal 2022.
- AbCellera Biologics Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $5.26M, a 88.83% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.61M 10-Q · filed 2026-08-05 | $5.41M derived: sum of 3 quarters · filed 2026-08-05 | $7.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.82M 10-Q · filed 2026-05-11 | $3.61M derived: sum of 2 quarters · filed 2026-05-11 | $5.60M derived: sum of 3 quarters · filed 2026-05-11 | $7.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.79M derived: sum of 2 quarters · filed 2026-02-24 | $5.38M derived: sum of 3 quarters · filed 2026-08-05 | $6.65M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.58M derived: sum of 2 quarters · filed 2026-08-05 | $4.85M 10-Q · filed 2025-11-06 | $6.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.86M 10-Q · filed 2026-08-05 | $4.20M derived: sum of 3 quarters · filed 2026-08-05 | $5.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-11 | $2.61M derived: sum of 2 quarters · filed 2026-05-11 | $3.99M derived: sum of 3 quarters · filed 2026-05-11 | $5.50M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.71M derived: sum of 2 quarters · filed 2026-02-24 | $4.23M derived: sum of 3 quarters · filed 2026-02-24 | $6.15M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.89M derived: sum of 2 quarters · filed 2025-11-06 | $4.81M 10-Q · filed 2025-11-06 | $6.39M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.44M 10-Q · filed 2025-08-07 | $5.01M derived: sum of 3 quarters · filed 2026-02-24 | $6.68M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.92M 10-Q · filed 2025-05-08 | $3.50M derived: sum of 2 quarters · filed 2026-02-24 | $5.17M derived: sum of 3 quarters · filed 2026-02-24 | $6.82M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.25M derived: sum of 2 quarters · filed 2026-02-24 | $4.89M derived: sum of 3 quarters · filed 2026-02-24 | $6.50M 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $3.32M derived: sum of 2 quarters · filed 2024-11-04 | $4.93M 10-Q · filed 2024-11-04 | $6.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $3.25M 10-Q · filed 2024-08-06 | $4.83M derived: sum of 3 quarters · filed 2025-02-27 | $6.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.61M 10-Q · filed 2024-05-07 | $3.18M derived: sum of 2 quarters · filed 2025-02-27 | $4.75M derived: sum of 3 quarters · filed 2025-02-27 | $5.89M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.14M derived: sum of 2 quarters · filed 2025-02-27 | $4.28M derived: sum of 3 quarters · filed 2025-02-27 | $5.26M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.71M derived: sum of 2 quarters · filed 2023-11-02 | $3.69M 10-Q · filed 2023-11-02 | $4.58M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.12M 10-Q · filed 2023-08-03 | $3.01M derived: sum of 3 quarters · filed 2024-02-20 | $3.55M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $976.00K 10-Q · filed 2023-05-04 | $1.87M derived: sum of 2 quarters · filed 2024-02-20 | $2.41M derived: sum of 3 quarters · filed 2024-02-20 | $3.10M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $890.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.43M derived: sum of 2 quarters · filed 2024-02-20 | $2.12M derived: sum of 3 quarters · filed 2024-02-20 | $2.79M 10-K · filed 2024-02-20 |
| 2021-09-30 | $541.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.23M derived: sum of 2 quarters · filed 2022-11-08 | $1.90M 10-Q · filed 2022-11-08 | $2.00M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $693.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.35M 10-Q · filed 2022-08-09 | $1.45M derived: sum of 3 quarters · filed 2023-02-21 | $1.53M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $661.00K 10-Q · filed 2022-05-10 | $761.00K derived: sum of 2 quarters · filed 2023-02-21 | $837.00K derived: sum of 3 quarters · filed 2023-02-21 | $1.02M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $176.00K derived: sum of 2 quarters · filed 2023-02-21 | $362.00K derived: sum of 3 quarters · filed 2023-02-21 | $435.00K 10-K · filed 2023-02-21 |
| 2020-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $262.00K derived: sum of 2 quarters · filed 2021-11-10 | $335.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $186.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $259.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $73.00K 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $243.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |